Researchers from the United States and Spain recently found that lower-risk myelodysplastic syndromes patients may benefit from early treatment with a certain kind of stem cell transplant.
Specifically, the patients benefited from donor stem cell transplants without T-cells, a type of white blood cell.
Over 60 percent of patients experienced survival times greater than five years, and the rate of graft-versus-host disease, a common transplant-related complication, was low.
According to the researchers, these findings support the use of transplantation without…
Treatment with Sprycel yields low response rates and high rates of progression to leukemia in patients with higher-risk myelodysplastic syndromes, according to results from a recent small Phase 2 study.
The study authors found that 50 percent of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) progressed to leukemia.
However, the results also showed that patients who responded or maintained stable disease survived significantly longer than those who did not respond. The study investigators suggested that Sprycel could be…
Sequential treatment with Zolinza, idarubicin, and cytarabine is safe and highly effective in patients with acute myeloid leukemia and higher-risk myelodysplastic syndromes, according to results from a recent Phase 2 study.
The study authors also found that patients with mutations in the FLT-3 gene responded particularly well to the drug combination, yielding an overall response rate of 100 percent.
Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center in Houston presented these findings at the 2011 American Society of Hematology…
Results of a recent study show that myelodysplastic syndromes patients who are in poor health and therefore ineligible for clinical trials may benefit from treatment with Vidaza and Zolinza.
The study authors found that the efficacy and safety of the combination therapy were similar to those of other treatment regimens commonly tested in clinical trials.
They concluded that their findings support treatment for patients who are ineligible for clinical trials, and they suggested that current eligibility criteria for Phase 1/2…